Oncology Institute, Inc. (TOI) awards 31,124 RSUs to board director
Rhea-AI Filing Summary
STOLPER MARK reported acquisition or exercise transactions in this Form 4 filing.
Oncology Institute, Inc. director Mark Stolper reported an equity compensation grant of 31,124 shares of Common Stock in the form of restricted stock units (RSUs) on 2026-07-27. Each RSU entitles him to receive one share of common stock upon settlement and vests in full on the date of the company’s 2027 annual meeting of stockholders, contingent on his continued service through that date. Following this award, Stolper directly holds 56,957 shares of common stock. The RSUs were granted at a stated price of $0.00 per share, reflecting their nature as a compensation grant rather than a market purchase.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 31,124 shares
Net Buy
1 txn
Insider
STOLPER MARK
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock F1 | 31,124 | $0.00 | $0.00 |
Holdings After Transaction:
Common Stock — 56,957 shares (Direct)
Footnotes (1)
- F1. Represents grant of restricted stock units (RSUs), each of which entitle the Reporting Person to receive one share of the Issuer's common stock upon settlement. The RSUs vest in full on the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service with the Issuer on the vesting date.
Key Figures
RSUs granted: 31,124 shares
Shares held after transaction: 56,957 shares
Grant price per RSU: $0.00 per share
+1 more
4 metrics
RSUs granted
31,124 shares
Restricted stock units granted to director on 2026-07-27
Shares held after transaction
56,957 shares
Director’s direct common stock holdings following the RSU grant
Grant price per RSU
$0.00 per share
Stated price for the compensation grant of RSUs
Vesting event
2027 annual meeting of stockholders
RSUs vest in full on the date of the 2027 annual meeting, subject to continued service
Key Terms
restricted stock units (RSUs), vest in full, settlement, annual meeting of stockholders
4 terms
restricted stock units (RSUs) financial
"Represents grant of restricted stock units (RSUs), each of which entitle the Reporting Person"
Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.
vest in full financial
"The RSUs vest in full on the date of the Issuer's 2027 annual meeting"
settlement financial
"each of which entitle the Reporting Person to receive one share ... upon settlement"
Settlement is the process of completing a financial transaction, like buying or selling a stock, by transferring money and ownership between parties. It ensures that both the buyer gets the asset and the seller gets paid, making the deal official. Without settlement, the transaction wouldn't be finalized or legally recognized.
annual meeting of stockholders regulatory
"on the date of the Issuer's 2027 annual meeting of stockholders"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did Oncology Institute, Inc. (TOI) director Mark Stolper report in this Form 4?
Mark Stolper reported a grant of 31,124 restricted stock units of Oncology Institute, Inc. common stock. These RSUs are a form of equity compensation that convert into shares upon settlement rather than a market purchase of stock.
When do the new RSUs for Oncology Institute (TOI) director Mark Stolper vest?
The 31,124 RSUs vest in full on the date of Oncology Institute’s 2027 annual meeting of stockholders. Vesting is conditioned on Stolper’s continued service with the company through that meeting date.
Was cash paid for the RSUs granted to Oncology Institute (TOI) director Mark Stolper?
No cash was paid; the RSUs were granted at a stated price of $0.00 per share. This reflects a compensation award rather than a purchase of Oncology Institute common stock in the open market.
What does each RSU reported by Oncology Institute (TOI) for Mark Stolper represent?
Each RSU entitles the reporting person to receive one share of Oncology Institute common stock upon settlement. The units are subject to vesting conditions tied to continued service and the company’s 2027 annual meeting.